Figure 2.
(A) Expression levels of apoptotic and anti-apoptotic mRNAs in asafetida-treated senescent cells. The expression of BCL2 was increased in the groups treated with 5 × 10−8 and 10−7 g/mL of asafetida compared with the control group (P < 0.01). Also, in those groups, the expression rates of apoptotic markers were significantly reduced as compared with the control group while in the groups treated with 5 × 10−7 and 10−6 g/mL of asafetida, the expression rates of apoptotic markers were increased. (B) Western blot assay for BCL2 protein in different groups (*P < 0.05 and $P < 0.01, compared with the control group).